RiverVest Venture Fund IV, L.P. 4
4 · Xilio Therapeutics, Inc. · Filed Oct 26, 2021
Insider Transaction Report
Form 4Exit
RiverVest Venture Fund IV, L.P.
10% Owner
Transactions
- Conversion
Common Stock
[F1][F2][F3]2021-10-26+832,120→ 832,120 total(indirect: See Footnotes) - Conversion
Common Stock
[F1][F2][F3]2021-10-26+359,324→ 1,191,444 total(indirect: See Footnotes) - Purchase
Common Stock
[F4][F2][F3]2021-10-26$16.00/sh+250,000$4,000,000→ 1,441,444 total(indirect: See Footnotes) - Conversion
Series B Preferred Stock
[F1][F2][F3]2021-10-26−832,120→ 0 total(indirect: See Footnotes)→ Common Stock (832,120 underlying) - Conversion
Series B Preferred Stock
[F1][F2][F3]2021-10-26−359,324→ 0 total(indirect: See Footnotes)→ Common Stock (359,324 underlying)
Footnotes (4)
- [F1]Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into 1 share of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 26, 2021. The shares have no expiration date.
- [F2]The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest IV") are indirectly held by RiverVest Venture Partners IV, L.P. ("RiverVest Partners IV"), which is the general partner of RiverVest IV. RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV.
- [F3]The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and Niall O'Donnell. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers share voting and dispositive power with regard to the securities directly held by RiverVest Venture Fund IV, L.P.
- [F4]RiverVest IV purchased the shares in the Issuer's initial public offering.
Signature
/s/ Jay Schmelter, Manager of RiverVest Venture Partners IV, LLC|2021-10-26